AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00922285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Evaluated at baseline, week 1 and week 6 of art therapy
Study NCT00922285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stress management therapy
Description: 6 weekly 60 minute sessions
Study NCT00743769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thymosin beta 4
Description: Single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD of thymosin beta 4
Study NCT00743769 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single bolus injections of ascending doses of 0.00 mg QD of thymosin beta 4
Study NCT02207010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: All patients receive a single dose of the oral study drug prior to surgery for resection of GBM.
Study NCT03491176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT03491176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan
Study NCT03491176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03491176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04466748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium enteric-coated tablet
Description: Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration.
Study NCT04466748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
Study NCT02823951 — intervention group
Intervention type: DRUG
Intervention: Rebif
Study NCT02404740 — intervention group
Intervention type: DEVICE
Intervention: Pulse oximetry
Description: Pulse oximetry
Study NCT02823951 — intervention group
Intervention type: DRUG
Intervention: Tecfidera
Study NCT01564134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine
Description: hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg
Study NCT01004770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-145 (AN113111) Injection
Description: 40 healthy volunteers (10 per treatment group) will receive AH113111 320 mg I/mL at 1 of 4 possible doses (300, 450, 600, or 900 mg I/kg) as a single intravenous (IV) administration.
Study NCT01004770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque (iodixanol) Injection
Description: An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
Study NCT02003495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCV-ACYW135 Vaccine Group
Description: 0.5ml, intramuscular
Study NCT02003495 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MPV-ACYW135 Vaccine Group
Description: 0.5ml, intramuscular
Study NCT02003495 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MPV-A Vaccine Group
Description: 0.5ml, intramuscular
Study NCT02003495 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MCV-AC Vaccine Group
Description: 0.5ml, intramuscular
Study NCT02003495 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hib Vaccine Group
Description: 0.5ml, intramuscular
Study NCT00987987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: donor lymphocyte infusion
Description: regulatory T cells depletion
Study NCT02424981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold inspiratory muscle training
Description: Inspiratory muscle training
Study NCT03404661 — intervention group
Intervention type: DRUG
Intervention: Synthetic Human Secretin
Description: Subjects will receive a dose of 0.2ng/kg while the endoscope is positioned in the second portion of the duodenum.
Study NCT00729235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ovatio CRT 6750
Description: Slow VT zone programmed as a Monitoring zone (Monitoring arm)
Study NCT00729235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ovatio CRT 6750
Description: Slow VT zone programmed with ATP therapies (therapy arm).
Study NCT03971942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral ABMT
Description: In the neutral attention bias, there are 108 pairs of neutral-negative words, 54 pairs of which are used in the training group and 54 pairs of which are used in the placebo group. The word pairs in each group are repeated 4 times, with a total of 216 trial. Participants received 8 sessions over 2 weeks (1 session every other day).In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the neutral word position and 10% of the targets appear in the negative word position, while 50% of the targets in the placebo group appear in the neutral word position and 50% of the targets appear in the negative word position.
Study NCT03971942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive ABMT
Description: In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 8 sessions over 2 weeks (1 session every other day). In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position, while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
Study NCT04474002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4L Klean Prep®
Description: Patients allocated to the control group shall mix two sachets of PEG in 2L water. At 6pm the evening before examination, they shall consume 250ml solution every 15mins, and finish in 2hours. At 7am the day of examination, drink another 2L Klean-prep in 2 hours.
Study NCT04474002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1L Klean prep® and 2 sachets Picoprep®
Description: Patients allocated to the study group shall mix each sachet of Picoprep® in 150ml warm water. The patient shall take the 1st dose at 4pm the day before procedure followed by at least five 250ml drinks of clear fluid before the next dose. The 2nd dose shall be taken approximately 6hrs later and followed by at least three 250ml drinks of clear fluid before bed. On 7am the day of procedure, they shall take 1L PEG in 1 hour.
Study NCT02203747 — intervention group
Intervention type: OTHER
Intervention: Administration of patient self-assessment
Study NCT01938976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAJ Plus (Adolescent Asthma Action in Jordan) Plus the added class smoke free pledge
Description: Its is a school-based peer-led asthma and smoking prevention program that aims at improving asthma control and lowering nicotine dependence among smokers.
Study NCT04616417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Investigational Oocyte Cryopreservation
Description: Transvaginal oocyte retrieval under ultrasound guidance
Study NCT03058510 — intervention group
Intervention type: PROCEDURE
Intervention: Frequency domain optical coherence tomography
Description: OCT is an established medical imaging technique that uses light to capture high-resolution, three-dimensional images of blood vessels
Study NCT03333525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calculation of insulin dosages for different meals
Description: Calculation of insulin dosages For CARB counting meals using insulin-carbohydrate ratio for dosing mealtime boluses. For fat protein counting meal ICR and additionally fat-protein unit were used for dosing of mealtime boluses.
Study NCT03333525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calculation of insulin dosages for different meals
Description: Calculation of insulin dosages For CARB counting meals using insulin-carbohydrate ratio for dosing mealtime boluses. For fat protein counting meal ICR and additionally fat-protein unit were used for dosing of mealtime boluses.
Study NCT02027779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GreenGene™ F
Description: Prophylaxis safety and efficacy substudy:~intra venous infusion, 30 ± 10 IU/kg infusions 3 times per week with dose escalation to 45 ± 10 IU/kg if appropriate, for 50 exposure days
Study NCT02027779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GreenGene™ F
Description: On-demand safety and efficacy substudy:~minor bleed = 20 ± 10 IU/kg moderate bleed = 30 ± 10 IU/kg major bleed = 30 - 50 IU/kg
Study NCT04570566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: horizontal alveolar ridge augmentation
Description: evaluate the potential application of resorbable pericardium membrane to augment localized alveolar ridge defects in esthetic zone, from histological, radiographical and clinical aspects in comparison with titanium mish for the subsequent placement of dental implants
Study NCT03646799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: test drug
Study NCT01431755 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane SubQ
Description: Treatment with up to 2 ml of the product
Study NCT01431755 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane SubQ Lidocaine
Description: Treatment with up to 2 ml of the product
Study NCT00545558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 600 mg tablet taken orally daily
Study NCT00545558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally daily
Study NCT03646799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D484
Description: reference drug
Study NCT02139722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Doctor, PA + PPN
Description: The intervention consists of a Video Doctor and Provider Alert. For the Video Doctor, we will develop a series of 30-60 seconds video clips, a branching algorithm, and a mobile application linking the baseline survey to the clips. The Provider Alert is a point-of-care reminder printout generated by the mobile application to facilitate patient-provider communication. The intervention integrates guidelines, literature, guidance from the Systems Model, our prior work, and input from patients and providers.
Study NCT01000168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill therapy and conventional walking therapy.
Description: The experimental group received 30 sessions of treadmill therapy with body weight support for a time period of 10 weeks.~The conventional group received traditional walking therapy for the same time period.
Study NCT01000168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill therapy and conventional walking therapy.
Description: The experimental group received 30 sessions of treadmill therapy with body weight support for a time period of 10 weeks.~The conventional group received traditional walking therapy for the same time period.
Study NCT00361374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: eicosapentaenoic acid
Description: 1 gram/day
Study NCT00361374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid
Description: 1 gram/day
Study NCT00361374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 980 milligram/day
Study NCT03274869 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02858050 — intervention group
Intervention type: DEVICE
Intervention: Portal-724 MEMs Cap
Study NCT03107364 — intervention group
Intervention type: OTHER
Intervention: Hospital stay
Description: Collection of hospital lengths of stay and readmissions
Study NCT04205331 — intervention group
Intervention type: DEVICE
Intervention: Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients
Description: Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients
Study NCT01070212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soft gum
Description: . Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
Study NCT01070212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: firm gum
Description: . Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
Study NCT01070212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no gum
Description: . Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
Study NCT05454644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person-Centred Prescription Model
Description: Step 1: Identify patients with advanced chronic condition and limited life expectancy.~Step 2: Interview with patients or closes caregiver.~Step 3: Medication Review~The clinical pharmacist conduct a structured medication review based on the medication appropriateness index (MAI):~* Indication/effectiveness: Product information, STOPPFrail (Screening Tool of Older Persons' Prescriptions in Frail adults with limited life expectancy) criteria and Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.~* Dosage adjustment: Product Information and Lexi-Comp's Geriatric Dosage Handbook.~* Correct and practical directions: Medication Regimen Complexity Index (MRCI).~* Drug-drug interactions: Bot Plus/Beers Criteria and drug burden index (DBI), which measures dose-dependent anticholinergic and sedative loads.~* Drug-disease interactions: Beers Criteria.~* Duplication, duration and cost-effectiveness: Product information.~Step 4: Treatment Plan
Study NCT00497289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipofundin MCT/LCT 20 %
Description: daily i.v. infusion for up to 5 days
Study NCT00497289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipidem 20%
Description: daily i.v. infusion for up to 5 days
Study NCT04453280 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative analysis of anti-SARS-CoV-2-antibodies
Description: Plasma sampling will be collected and archived for subsequent quantitative analysis of anti-SARS-CoV-2 antibodies - IgG, IgM and IgA.
Study NCT03999437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERBINAFINE HYDROCHLORIDE (1%)
Description: Topical liquid solution
Study NCT03999437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BUTENAFINE HYDROCHLORIDE (1%)
Description: Topical liquid solution
Study NCT03999437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: Topical liquid solution
Study NCT03144856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg, po, qd, every 4 weeks.
Study NCT02405507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: wheat bread with wheat germ
Study NCT02405507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: wheat bread without wheat germ
Study NCT03795103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulator
Description: A 12-week program of neuromuscular electrical stimulation
Study NCT03795103 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Walking sessions
Description: A 12-week program of walking sessions performed outdoors and independently
Study NCT03795103 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Advices
Description: The usual practice associated with an information leaflet outlining tips for active living and walking.
Study NCT02541656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study of preload dependence indices after volume expansion in laparoscopy with Saldinger technique.
Description: The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
Study NCT01055249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen, Hydrocortisone
Description: Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
Study NCT01055249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone
Description: Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
Study NCT03697421 — intervention group
Intervention type: OTHER
Intervention: Relationship Education
Description: We will provide the following 4 activities: 1) marriage and relationship education \[using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.).
Study NCT03697421 — intervention group
Intervention type: OTHER
Intervention: Employment Services
Description: For couples in need of job search, job retention, and career advancement services, we will provide employment services.
Study NCT04185558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGraft
Description: Whole Blood Clot (WBC) gel
Study NCT04185558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap
Study NCT02203240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa
Study NCT02203240 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03581981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure for Primary Care (PE-PC)
Description: Brief version of Prolonged Exposure (PE) provided in 30 minute sessions in primary care (PC)
Study NCT03581981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Veterans assigned to Primary Care (PC) Mental Health Integration (PCMHI)-Treatment as Usual (TAU) will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty MH), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
Study NCT00373399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Marijuana (0% THC)
Description: Placebo marijuana was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
Study NCT00373399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low THC marijuana (1.8 %THC)
Description: Active marijuana (1.8 % THC) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.